메뉴 건너뛰기




Volumn 1113, Issue , 2007, Pages 202-216

Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress

Author keywords

Cancer therapy; HSP molecular chaperone; Inhibitors

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DIMETHYLAMINOETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; 8 ARYLSULFANYL ADENINE DERIVATIVE 37; ADENINE DERIVATIVE; ADENOSINE TRIPHOSPHATASE; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; BIOLOGICAL MARKER; CCT 018159; CELESTROL; CF 237; CHAPERONE; CNF 2024; GEDUNIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IPI 504; NATURAL PRODUCT; NOVOBIOCIN; NUCLEOTIDE BINDING PROTEIN; ONCOPROTEIN; PU 24FCL; RADICICOL; RESORCINOL DERIVATIVE; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VER 49009; VER 50589;

EID: 35348890981     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1391.012     Document Type: Conference Paper
Times cited : (480)

References (88)
  • 1
    • 33746430408 scopus 로고    scopus 로고
    • Drugging the cancer kinome: Progress and challenges in developing personalized molecular cancer therapeutics
    • WORKMAN, P. 2005. Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. Cold Spring Harb. Symp. Quant. Biol. 70: 499-515.
    • (2005) Cold Spring Harb. Symp. Quant. Biol , vol.70 , pp. 499-515
    • WORKMAN, P.1
  • 2
    • 33751106653 scopus 로고    scopus 로고
    • New approaches to molecular cancer therapeutics
    • COLLINS, I & P. WORKMAN. 2006. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2: 689-700.
    • (2006) Nat. Chem. Biol , vol.2 , pp. 689-700
    • COLLINS, I.1    WORKMAN, P.2
  • 3
    • 33749447286 scopus 로고    scopus 로고
    • AKT and cancer-is it all mTOR?
    • ROSEN, N & Q.B. SHE. 2006. AKT and cancer-is it all mTOR? Cancer Cell. 10: 254-256.
    • (2006) Cancer Cell , vol.10 , pp. 254-256
    • ROSEN, N.1    SHE, Q.B.2
  • 5
    • 0037025173 scopus 로고    scopus 로고
    • Cancer. Addiction to oncogenes - the Achilles heal of cancer
    • WEINSTEIN, I.B. 2002. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297: 63-64.
    • (2002) Science , vol.297 , pp. 63-64
    • WEINSTEIN, I.B.1
  • 6
    • 33749993417 scopus 로고    scopus 로고
    • The consensus coding sequences of human breast and colorectal cancers
    • SJOBLOM, T., S. JONES, L.D. WOOD, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
    • (2006) Science , vol.314 , pp. 268-274
    • SJOBLOM, T.1    JONES, S.2    WOOD, L.D.3
  • 7
    • 33947101019 scopus 로고    scopus 로고
    • Patterns of somatic mutation in human cancer genomes
    • GREENMAN, C., P. STEPHENS, R. SMITH, et al. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
    • (2007) Nature , vol.446 , pp. 153-158
    • GREENMAN, C.1    STEPHENS, P.2    SMITH, R.3
  • 8
    • 32944457518 scopus 로고    scopus 로고
    • mTORinhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    • O'REILLY, K.E., F. ROJO, Q.B. SHE, et al. 2006.mTORinhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66: 1500-1508.
    • (2006) Cancer Res , vol.66 , pp. 1500-1508
    • O'REILLY, K.E.1    ROJO, F.2    SHE, Q.B.3
  • 9
    • 26644449670 scopus 로고    scopus 로고
    • The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
    • SHE, Q.B., D.B. SOLIT, Q. YE, et al. 2005. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8: 287-297.
    • (2005) Cancer Cell , vol.8 , pp. 287-297
    • SHE, Q.B.1    SOLIT, D.B.2    YE, Q.3
  • 11
    • 1542298267 scopus 로고    scopus 로고
    • Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
    • WORKMAN, P. 2004. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 206: 149-157.
    • (2004) Cancer Lett , vol.206 , pp. 149-157
    • WORKMAN, P.1
  • 12
    • 33746191768 scopus 로고    scopus 로고
    • Inhibitors of the HSP90 molecular chaperone: Current status
    • SHARP, S. & P. WORKMAN. 2006. Inhibitors of the HSP90 molecular chaperone: current status. Adv. Cancer Res. 95: 323-348.
    • (2006) Adv. Cancer Res , vol.95 , pp. 323-348
    • SHARP, S.1    WORKMAN, P.2
  • 13
    • 4344674482 scopus 로고    scopus 로고
    • Targeting multiple signal transduction pathways through inhibition of Hsp90
    • ZHANG, H. & F. BURROWS. 2004. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 82: 488-499.
    • (2004) J. Mol. Med , vol.82 , pp. 488-499
    • ZHANG, H.1    BURROWS, F.2
  • 14
    • 34250162144 scopus 로고    scopus 로고
    • Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells
    • XU, W. & L. NECKERS. 2007. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin. Cancer Res. 13: 1625-1629.
    • (2007) Clin. Cancer Res , vol.13 , pp. 1625-1629
    • XU, W.1    NECKERS, L.2
  • 15
    • 33746417580 scopus 로고    scopus 로고
    • Hsp90: A novel target for cancer therapy
    • SOLIT, D.B. & N. ROSEN. 2006. Hsp90: a novel target for cancer therapy. Curr. Top. Med. Chem. 6: 1205-1214.
    • (2006) Curr. Top. Med. Chem , vol.6 , pp. 1205-1214
    • SOLIT, D.B.1    ROSEN, N.2
  • 17
    • 25844519550 scopus 로고    scopus 로고
    • HSP90 and the chaperoning of cancer
    • WHITESELL, L.& S. LINDQUIST. 2005. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5: 761-772.
    • (2005) Nat. Rev. Cancer , vol.5 , pp. 761-772
    • WHITESELL, L.1    LINDQUIST, S.2
  • 18
    • 34250561475 scopus 로고
    • A new puffing pattern induced by temperature shock and DNP in Drosophila
    • RITOSSA, F. 1962. A new puffing pattern induced by temperature shock and DNP in Drosophila. Experentia 19: 571-573.
    • (1962) Experentia , vol.19 , pp. 571-573
    • RITOSSA, F.1
  • 19
    • 0030154255 scopus 로고    scopus 로고
    • Discovery of the heat shock response
    • RITOSSA, F. 1996. Discovery of the heat shock response. Cell Stress Chaperones 1: 97-98.
    • (1996) Cell Stress Chaperones , vol.1 , pp. 97-98
    • RITOSSA, F.1
  • 20
    • 33746364784 scopus 로고    scopus 로고
    • Structure and mechanism of Hsp90 molecular chaperone machinery
    • PEARL, L.H. & C. PRODROMOU. 2006. Structure and mechanism of Hsp90 molecular chaperone machinery. Ann. Rev. Biochem. 75: 271-294.
    • (2006) Ann. Rev. Biochem , vol.75 , pp. 271-294
    • PEARL, L.H.1    PRODROMOU, C.2
  • 21
    • 15544372341 scopus 로고    scopus 로고
    • Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex
    • XU, W., X. YUAN, Z. XIANG, et al. 2005. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat. Struct. Mol. Biol. 12: 120-126.
    • (2005) Nat. Struct. Mol. Biol , vol.12 , pp. 120-126
    • XU, W.1    YUAN, X.2    XIANG, Z.3
  • 22
    • 34248195608 scopus 로고    scopus 로고
    • High HSP90 expression is associated with decreased survival in breast cancer
    • PICK, E., Y. KLUGER, J.M. GILTNANE, et al. 2007. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 67: 2932-2937.
    • (2007) Cancer Res , vol.67 , pp. 2932-2937
    • PICK, E.1    KLUGER, Y.2    GILTNANE, J.M.3
  • 23
    • 33746379315 scopus 로고    scopus 로고
    • Using natural product inhibitors to validate HSP90 as a molecular target in cancer
    • NECKERS, L. 2006. Using natural product inhibitors to validate HSP90 as a molecular target in cancer. Curr. Med. Chem. 6: 1163-1171.
    • (2006) Curr. Med. Chem , vol.6 , pp. 1163-1171
    • NECKERS, L.1
  • 24
    • 0141819958 scopus 로고    scopus 로고
    • The stress response: Implications for the development of Hp90 inhibitors
    • WHITESELL, L., R. BAGATELL & R. FALSEY. 2003. The stress response: implications for the development of Hp90 inhibitors. Curr. Cancer Drug Targets 3: 349-358.
    • (2003) Curr. Cancer Drug Targets , vol.3 , pp. 349-358
    • WHITESELL, L.1    BAGATELL, R.2    FALSEY, R.3
  • 26
    • 0141484615 scopus 로고    scopus 로고
    • A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
    • KAMAL, A., L. THAO, J. SENSINTAFFAR, et al. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410.
    • (2003) Nature , vol.425 , pp. 407-410
    • KAMAL, A.1    THAO, L.2    SENSINTAFFAR, J.3
  • 27
    • 28244444919 scopus 로고    scopus 로고
    • Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin
    • DA ROCHA DIAS, S., F. FRIEDLOS, Y. LIGHT, et al. 2005. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65: 10686-10691.
    • (2005) Cancer Res , vol.65 , pp. 10686-10691
    • DA ROCHA DIAS, S.1    FRIEDLOS, F.2    LIGHT, Y.3
  • 28
    • 30444441778 scopus 로고    scopus 로고
    • V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in Response to Hsp90 inhibitors
    • GRBOVIC, O.M., A.D. BASSO, A. SAWAI, et al. 2006. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in Response to Hsp90 inhibitors. Proc. Natl. Acad. Sci. USA. 103: 57-62.
    • (2006) Proc. Natl. Acad. Sci. USA , vol.103 , pp. 57-62
    • GRBOVIC, O.M.1    BASSO, A.D.2    SAWAI, A.3
  • 29
    • 22244485706 scopus 로고    scopus 로고
    • Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins
    • SHIMAMURA, T., A.M. LOWELL, J.A. ENGELMAN & G.I. SHAPIRO. 2005. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 65: 6401-6408.
    • (2005) Cancer Res , vol.65 , pp. 6401-6408
    • SHIMAMURA, T.1    LOWELL, A.M.2    ENGELMAN, J.A.3    SHAPIRO, G.I.4
  • 30
    • 0032569851 scopus 로고    scopus 로고
    • Hsp90 as a capacitor for morphological evolution
    • RUTHERFORD, S.L. & S. LINDQUIST. 1998. Hsp90 as a capacitor for morphological evolution. Nature 396: 336-342.
    • (1998) Nature , vol.396 , pp. 336-342
    • RUTHERFORD, S.L.1    LINDQUIST, S.2
  • 31
    • 34047237073 scopus 로고    scopus 로고
    • YEYATI, P.L., R.M. BANCEWICZ, J.M. MAULE & V. VAN HEYNINGEN. 2007. Hsp90 selectively modulates phenotype in vertebrate development. PLoS Genetics 43: 431-447.
    • YEYATI, P.L., R.M. BANCEWICZ, J.M. MAULE & V. VAN HEYNINGEN. 2007. Hsp90 selectively modulates phenotype in vertebrate development. PLoS Genetics 43: 431-447.
  • 32
    • 33746377987 scopus 로고    scopus 로고
    • Inhibitors of the HSP90 molecular chaperone: Attacking the master regulator in cancer
    • MCDONALD, E., P. WORKMAN & K. JONES. 2007. Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr. Top. Med. Chem. 6: 1091-1107.
    • (2007) Curr. Top. Med. Chem , vol.6 , pp. 1091-1107
    • MCDONALD, E.1    WORKMAN, P.2    JONES, K.3
  • 33
    • 0028064940 scopus 로고
    • Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation
    • WHITESELL, L., E.G. MIMNAUGH, B. DE COSTA, et al. 1994. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 91: 8324-8328.
    • (1994) Proc. Natl. Acad. Sci. USA , vol.91 , pp. 8324-8328
    • WHITESELL, L.1    MIMNAUGH, E.G.2    DE COSTA, B.3
  • 34
    • 0032554763 scopus 로고    scopus 로고
    • Targeting of the protein chaperone HSP90, by the transformation suppressing agent, radicicol
    • SHARMA, S.V., T. AGATSUMA & H. NAKANO. 1998. Targeting of the protein chaperone HSP90, by the transformation suppressing agent, radicicol. Oncogene 16: 2639-2645.
    • (1998) Oncogene , vol.16 , pp. 2639-2645
    • SHARMA, S.V.1    AGATSUMA, T.2    NAKANO, H.3
  • 35
    • 0141596941 scopus 로고    scopus 로고
    • Overview: Translating Hsp90 biology into Hsp90 drugs
    • WORKMAN, P. 2003. Overview: translating Hsp90 biology into Hsp90 drugs. Curr. Cancer Drug Targets 3: 297-300.
    • (2003) Curr. Cancer Drug Targets , vol.3 , pp. 297-300
    • WORKMAN, P.1
  • 36
    • 0032959590 scopus 로고    scopus 로고
    • Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin
    • ROE, S.M., C. PRODROMOU, R. O'BRIEN, et al. 1999. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42: 260-266.
    • (1999) J. Med. Chem , vol.42 , pp. 260-266
    • ROE, S.M.1    PRODROMOU, C.2    O'BRIEN, R.3
  • 37
    • 0036718795 scopus 로고    scopus 로고
    • ATPases as drug targets: Learning from their structure
    • CHENE, P. 2002. ATPases as drug targets: learning from their structure. Nat. Rev. Drug Discov. 1: 665-673.
    • (2002) Nat. Rev. Drug Discov , vol.1 , pp. 665-673
    • CHENE, P.1
  • 39
    • 23044441106 scopus 로고    scopus 로고
    • Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
    • BANERJI, U., A O'DONNELL, M. SCURR, et al. 2005. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 23: 4152-4161.
    • (2005) J. Clin. Oncol , vol.23 , pp. 4152-4161
    • BANERJI, U.1    O'DONNELL, A.2    SCURR, M.3
  • 40
    • 34250197902 scopus 로고    scopus 로고
    • Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
    • SOLIT, D.B., S.P. IVY, C. KOPIL, et al. 2007. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin. Cancer Res. 13: 1775-1782.
    • (2007) Clin. Cancer Res , vol.13 , pp. 1775-1782
    • SOLIT, D.B.1    IVY, S.P.2    KOPIL, C.3
  • 42
    • 1942485334 scopus 로고    scopus 로고
    • 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models
    • BURGER A.M., H.H. FIEBIG, S.F. STINSON & E.A. SAUSVILLE. 2004. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15: 377-387.
    • (2004) Anticancer Drugs , vol.15 , pp. 377-387
    • BURGER, A.M.1    FIEBIG, H.H.2    STINSON, S.F.3    SAUSVILLE, E.A.4
  • 43
    • 33751258297 scopus 로고    scopus 로고
    • Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anticancer agent directed against Hsp90
    • SYDOR J.R., E. NORMANT, C.S. PIEN, et al. 2006. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anticancer agent directed against Hsp90. Proc. Natl. Acad. Sci. USA 103: 17408-17413.
    • (2006) Proc. Natl. Acad. Sci. USA , vol.103 , pp. 17408-17413
    • SYDOR, J.R.1    NORMANT, E.2    PIEN, C.S.3
  • 44
    • 0033579175 scopus 로고    scopus 로고
    • DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
    • KELLAND, L.R., S.Y. SHARP, P.M. ROGERS, et al. 1999. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 91: 1940-1949.
    • (1999) J. Natl. Cancer Inst , vol.91 , pp. 1940-1949
    • KELLAND, L.R.1    SHARP, S.Y.2    ROGERS, P.M.3
  • 45
    • 0034655207 scopus 로고    scopus 로고
    • Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases
    • ZHENG, F.F., S. KUDUK, G. CHIOSIS, et al. 2000. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res. 15: 20904-2094.
    • (2000) Cancer Res , vol.15 , pp. 20904-22094
    • ZHENG, F.F.1    KUDUK, S.2    CHIOSIS, G.3
  • 46
    • 33846629429 scopus 로고    scopus 로고
    • Dimeric ansamycins - a new class of antitumor Hsp90 modulators with prolonged inhibitory activity
    • ZHANG, H., Y.C. YANG, L. ZHANG, et al. 2006. Dimeric ansamycins - a new class of antitumor Hsp90 modulators with prolonged inhibitory activity. Int. J. Cancer 120: 918-926.
    • (2006) Int. J. Cancer , vol.120 , pp. 918-926
    • ZHANG, H.1    YANG, Y.C.2    ZHANG, L.3
  • 48
    • 28144440479 scopus 로고    scopus 로고
    • Heat shock protein 90 inhibitors. A text book example of medicinal chemistry?
    • JANIN, Y.L. 2005. Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? J. Med. Chem. 48: 7503-7512.
    • (2005) J. Med. Chem , vol.48 , pp. 7503-7512
    • JANIN, Y.L.1
  • 49
    • 0035071607 scopus 로고    scopus 로고
    • A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells
    • CHIOSIS, G., M.N. TIMAUL, B. LUCAS, et al. 2001. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 8: 289-299.
    • (2001) Chem. Biol , vol.8 , pp. 289-299
    • CHIOSIS, G.1    TIMAUL, M.N.2    LUCAS, B.3
  • 50
    • 33746365169 scopus 로고    scopus 로고
    • Discovery and development of purine-scaffold Hsp90 inhibitors
    • CHIOSIS, G. 2006. Discovery and development of purine-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem. 6: 1183-1191.
    • (2006) Curr. Top. Med. Chem , vol.6 , pp. 1183-1191
    • CHIOSIS, G.1
  • 51
    • 3042637928 scopus 로고    scopus 로고
    • Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms
    • WRIGHT, L., X. BARRIL, B. DYMOCK, et al. 2004. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol. 11: 775-785.
    • (2004) Chem. Biol , vol.11 , pp. 775-785
    • WRIGHT, L.1    BARRIL, X.2    DYMOCK, B.3
  • 52
    • 17444416142 scopus 로고    scopus 로고
    • Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90
    • LLAUGER, L., H. HE, J. KIM, et al. 2005. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J. Med. Chem. 48: 2892-2905.
    • (2005) J. Med. Chem , vol.48 , pp. 2892-2905
    • LLAUGER, L.1    HE, H.2    KIM, J.3
  • 53
    • 33747500679 scopus 로고    scopus 로고
    • 7′-Substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors
    • ZHANG, L., J. FAN, K. VU, et al. 2006. 7′-Substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors. J. Med. Chem. 49: 5352-5362.
    • (2006) J. Med. Chem , vol.49 , pp. 5352-5362
    • ZHANG, L.1    FAN, J.2    VU, K.3
  • 54
    • 20644448390 scopus 로고    scopus 로고
    • The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors
    • CHEUNG, K.M., T.P. MATTHEWS, K. JAMES, et al. 2005. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 15: 3338-3343.
    • (2005) Bioorg. Med. Chem. Lett , vol.15 , pp. 3338-3343
    • CHEUNG, K.M.1    MATTHEWS, T.P.2    JAMES, K.3
  • 55
    • 33947210121 scopus 로고    scopus 로고
    • In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors
    • SHARP, S.Y., K. BOXALL, M. ROWLANDS, et al. 2007. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res. 67: 2206-2216.
    • (2007) Cancer Res , vol.67 , pp. 2206-2216
    • SHARP, S.Y.1    BOXALL, K.2    ROWLANDS, M.3
  • 56
    • 21244505104 scopus 로고    scopus 로고
    • Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design
    • DYMOCK, B.W., X. BARRILL, P.A. BROUGH, et al. 2005. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J. Med. Chem. 48: 4212-4215.
    • (2005) J. Med. Chem , vol.48 , pp. 4212-4215
    • DYMOCK, B.W.1    BARRILL, X.2    BROUGH, P.A.3
  • 57
    • 34248166042 scopus 로고    scopus 로고
    • Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
    • SHARP, S.Y, C. PRODROMOU, K. BOXALL, et al. 2007. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol. Cancer Ther. 6: 1198-1211.
    • (2007) Mol. Cancer Ther , vol.6 , pp. 1198-1211
    • SHARP, S.Y.1    PRODROMOU, C.2    BOXALL, K.3
  • 58
    • 0034711270 scopus 로고    scopus 로고
    • The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone
    • MARCU, M.G., A. CHADLI, I. BOUHOUCHE, et al. 2000. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275: 37181-37186.
    • (2000) J. Biol. Chem , vol.275 , pp. 37181-37186
    • MARCU, M.G.1    CHADLI, A.2    BOUHOUCHE, I.3
  • 59
    • 0034594644 scopus 로고    scopus 로고
    • Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins
    • MARCU, M.G., T.W. SCHULTE & L. NECKERS. 2000. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 92: 242-248.
    • (2000) J. Natl. Cancer Inst , vol.92 , pp. 242-248
    • MARCU, M.G.1    SCHULTE, T.W.2    NECKERS, L.3
  • 60
    • 25144435448 scopus 로고    scopus 로고
    • Hsp90 inhibitors identified from a library of novobiocin analogues
    • YU, X.M., G. SHEN, L. NECKERS, et al. 2005. Hsp90 inhibitors identified from a library of novobiocin analogues. J. Am. Chem. Soc. 127:12778-12779.
    • (2005) J. Am. Chem. Soc , vol.127 , pp. 12778-12779
    • YU, X.M.1    SHEN, G.2    NECKERS, L.3
  • 61
    • 33845306864 scopus 로고    scopus 로고
    • Novobiocin: Redesigning a DNA gyrase inhibitor for selective inhibition of hsp90
    • BURLISON, J.A., L. NECKERS, A.B. SMITH, et al. 2006. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J. Am. Chem. Soc. 128: 15529-15536.
    • (2006) J. Am. Chem. Soc , vol.128 , pp. 15529-15536
    • BURLISON, J.A.1    NECKERS, L.2    SMITH, A.B.3
  • 62
    • 0037012344 scopus 로고    scopus 로고
    • Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228
    • YU, X., M.G. GUO, L. NECKERS, D.M. NQUYEN, et al. 2002. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94: 504-513.
    • (2002) J. Natl. Cancer Inst , vol.94 , pp. 504-513
    • YU, X.1    GUO, M.G.2    NECKERS, L.3    NQUYEN, D.M.4
  • 63
    • 22844432021 scopus 로고    scopus 로고
    • Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors
    • BALI P, M. PRANPAT, J. BRADNER, et al. 2005. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280: 26729-26734.
    • (2005) J. Biol. Chem , vol.280 , pp. 26729-26734
    • BALI, P.1    PRANPAT, M.2    BRADNER, J.3
  • 64
    • 33846014703 scopus 로고    scopus 로고
    • An acetylation site in the middle domain of Hsp90 regulates chaperone function
    • SCROGGINS, B.T., K. ROBZYK, D. WANG, et al. 2007. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell. 25: 151-159.
    • (2007) Mol. Cell , vol.25 , pp. 151-159
    • SCROGGINS, B.T.1    ROBZYK, K.2    WANG, D.3
  • 65
    • 0034710542 scopus 로고    scopus 로고
    • Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone
    • CLARKE, P.A., I. HOSTEIN, U. BANERJI, et al. 2000. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19: 4125-4133.
    • (2000) Oncogene , vol.19 , pp. 4125-4133
    • CLARKE, P.A.1    HOSTEIN, I.2    BANERJI, U.3
  • 66
    • 33749433916 scopus 로고    scopus 로고
    • Gene expression signaturebased chemical genomic prediction identifies a novel class of HSP90 pathway modulators
    • HIERONYMUS, H., J. LAMB, K.N. ROSS, et al. 2006. Gene expression signaturebased chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10: 321-330.
    • (2006) Cancer Cell , vol.10 , pp. 321-330
    • HIERONYMUS, H.1    LAMB, J.2    ROSS, K.N.3
  • 67
    • 0037636527 scopus 로고    scopus 로고
    • Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90
    • MATTHEWS, R.C., C. RIGG, S. HODGETTS, et al. 2003. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47: 2208-2216.
    • (2003) Antimicrob. Agents Chemother , vol.47 , pp. 2208-2216
    • MATTHEWS, R.C.1    RIGG, C.2    HODGETTS, S.3
  • 68
    • 26444482073 scopus 로고    scopus 로고
    • Pharmacokineticpharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models
    • BANERJI, U., M. WALTON, F. RAYNAUD, et al. 2005. Pharmacokineticpharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin. Cancer Res. 11: 7023-7032.
    • (2005) Clin. Cancer Res , vol.11 , pp. 7023-7032
    • BANERJI, U.1    WALTON, M.2    RAYNAUD, F.3
  • 69
    • 33745086222 scopus 로고    scopus 로고
    • Identification of new biomarkers for clinical trials of Hsp90 inhibitors
    • ZHANG, H., D. CHUNG, Y.C. YANG, et al. 2006. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol. Cancer Ther. 5: 1256-1264.
    • (2006) Mol. Cancer Ther , vol.5 , pp. 1256-1264
    • ZHANG, H.1    CHUNG, D.2    YANG, Y.C.3
  • 70
    • 34147150867 scopus 로고    scopus 로고
    • Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin
    • MALONEY, A., P.A. CLARKE, S. NAABY- HANSEN, et al. 2007. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 67: 3239-5323.
    • (2007) Cancer Res , vol.67 , pp. 3239-5323
    • MALONEY, A.1    CLARKE, P.A.2    NAABY- HANSEN, S.3
  • 71
    • 33745574028 scopus 로고    scopus 로고
    • Early tumor response to Hsp90 therapy using HER2 PET: Comparison with 18F-FDG PET
    • SMITH-JONES, P.M., D. SOLIT, F. AFROZE, et al. 2006. Early tumor response to Hsp90 therapy using HER2 PET: Comparison with 18F-FDG PET. J. Nucl. Med. 47: 793-796.
    • (2006) J. Nucl. Med , vol.47 , pp. 793-796
    • SMITH-JONES, P.M.1    SOLIT, D.2    AFROZE, F.3
  • 72
    • 0344393470 scopus 로고    scopus 로고
    • Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models
    • CHUNG, Y.L., H. TROY, U. BANERJI, et al. 2003. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl. Cancer Inst. 95: 1624-1633.
    • (2003) J. Natl. Cancer Inst , vol.95 , pp. 1624-1633
    • CHUNG, Y.L.1    TROY, H.2    BANERJI, U.3
  • 73
    • 20044382800 scopus 로고    scopus 로고
    • Navigating the chaperone network: An interactive map of physical and genetic interactions mediated by the Hsp90 chaperone
    • ZHAO, R. , M. DAVEY, H. YA-CHIEH, et al. 2005. Navigating the chaperone network: an interactive map of physical and genetic interactions mediated by the Hsp90 chaperone. Cell 120: 715-727.
    • (2005) Cell , vol.120 , pp. 715-727
    • ZHAO, R.1    DAVEY, M.2    YA-CHIEH, H.3
  • 74
    • 33845804718 scopus 로고    scopus 로고
    • Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity
    • XU, W., X. YUAN, K. BEEBE, et al. 2007. Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity. Mol. Cell Biol. 27: 220-228.
    • (2007) Mol. Cell Biol , vol.27 , pp. 220-228
    • XU, W.1    YUAN, X.2    BEEBE, K.3
  • 75
    • 33746628448 scopus 로고    scopus 로고
    • Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation
    • KOGA, F., W. XU, T.S. KARPOVA, et al. 2006. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc. Natl. Acad. Sci. USA 103: 11318-1122.
    • (2006) Proc. Natl. Acad. Sci. USA , vol.103 , pp. 11318-21122
    • KOGA, F.1    XU, W.2    KARPOVA, T.S.3
  • 76
    • 0037444766 scopus 로고    scopus 로고
    • Heat shock protein 90 and Cdc37 interact with LKB1 and regulate its stability
    • BOUDEAU, J., M. DEAK, M.A. LAWLOR, et al. 2003. Heat shock protein 90 and Cdc37 interact with LKB1 and regulate its stability. Biochem. J. 370: 849-857.
    • (2003) Biochem. J , vol.370 , pp. 849-857
    • BOUDEAU, J.1    DEAK, M.2    LAWLOR, M.A.3
  • 77
    • 0346057795 scopus 로고    scopus 로고
    • Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37
    • NONY, P., H. GAUDE, M. ROSSEL, et al. 2003. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37. Oncogene 22: 9165-9175.
    • (2003) Oncogene , vol.22 , pp. 9165-9175
    • NONY, P.1    GAUDE, H.2    ROSSEL, M.3
  • 78
    • 2442464375 scopus 로고    scopus 로고
    • Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel hERG
    • FICKER, E, A.T. DENNIS, L. WANG, et al. 2003. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel hERG. Circ. Res. 92:87-100.
    • (2003) Circ. Res , vol.92 , pp. 87-100
    • FICKER, E.1    DENNIS, A.T.2    WANG, L.3
  • 79
    • 33847708258 scopus 로고    scopus 로고
    • Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury
    • GABRIELSON, K., D. BEDJA, S. PIN, et al. 2007. Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Res. 67: 1436-1441.
    • (2007) Cancer Res , vol.67 , pp. 1436-1441
    • GABRIELSON, K.1    BEDJA, D.2    PIN, S.3
  • 80
    • 21144432950 scopus 로고    scopus 로고
    • Heat shock protein 90 inhibitor, 17-allylamino-17- demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line
    • PRICE, J.T., J.M.W. QUINN, N.A. SIMS, et al. 2005. Heat shock protein 90 inhibitor, 17-allylamino-17- demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res. 65: 4929-4938.
    • (2005) Cancer Res , vol.65 , pp. 4929-4938
    • PRICE, J.T.1    QUINN, J.M.W.2    SIMS, N.A.3
  • 81
    • 33645470397 scopus 로고    scopus 로고
    • Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis
    • SANDERSON, S, M. VALENTI, S. GOWAN, et al. 2006. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol. Cancer Ther. 5: 522-532.
    • (2006) Mol. Cancer Ther , vol.5 , pp. 522-532
    • SANDERSON, S.1    VALENTI, M.2    GOWAN, S.3
  • 82
    • 0037119415 scopus 로고    scopus 로고
    • Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway
    • ISAACS, J.S., Y.J. JUNG, E.G. MIMNAUGH, et al. 2002. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 277: 29936-29944.
    • (2002) J. Biol. Chem , vol.277 , pp. 29936-29944
    • ISAACS, J.S.1    JUNG, Y.J.2    MIMNAUGH, E.G.3
  • 83
    • 33749352630 scopus 로고    scopus 로고
    • Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade
    • MIMNAUGH, E.G., W. XU, M. VOS, et al. 2006. Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade. Mol. Cancer Res. 4: 667-681.
    • (2006) Mol. Cancer Res , vol.4 , pp. 667-681
    • MIMNAUGH, E.G.1    XU, W.2    VOS, M.3
  • 84
    • 0034890377 scopus 로고    scopus 로고
    • Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner
    • BASSO, A., D. SOLIT, L. NORTON, et al. 2001. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res. 7: 2228-2236.
    • (2001) Clin. Cancer Res , vol.7 , pp. 2228-2236
    • BASSO, A.1    SOLIT, D.2    NORTON, L.3
  • 85
    • 33745071182 scopus 로고    scopus 로고
    • Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT
    • SAIN, N, B. KRISHNAN, M.G. ORMEROD, et al. 2006. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol. Cancer Ther. 5: 1197-1208.
    • (2006) Mol. Cancer Ther , vol.5 , pp. 1197-1208
    • SAIN, N.1    KRISHNAN, B.2    ORMEROD, M.G.3
  • 86
    • 33847369469 scopus 로고    scopus 로고
    • A high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins
    • DICKEY, C.A., A. KAMAL, K. LUNDGREN, et al. 2007. A high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 117: 648-658.
    • (2007) J. Clin. Invest , vol.117 , pp. 648-658
    • DICKEY, C.A.1    KAMAL, A.2    LUNDGREN, K.3
  • 87
    • 33750842131 scopus 로고    scopus 로고
    • Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis
    • WANG, X., J. VENABLE, P. LAPOINTE, et al. 2006. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127: 803-815.
    • (2006) Cell , vol.127 , pp. 803-815
    • WANG, X.1    VENABLE, J.2    LAPOINTE, P.3
  • 88
    • 34147099104 scopus 로고    scopus 로고
    • A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation
    • HARDCASTLE, A., P. TOMLIN, C. NORRIS, et al. 2007. A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation. Mol. Cancer Ther. 6: 1112-1122.
    • (2007) Mol. Cancer Ther , vol.6 , pp. 1112-1122
    • HARDCASTLE, A.1    TOMLIN, P.2    NORRIS, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.